Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes

Oliver Schnell; Tadej Battelino; Richard Bergenstal; Matthias Blüher; Michael Böhm; Frank Brosius; Richard D. Carr; Antonio Ceriello; Thomas Forst; Francesco Giorgino; Bruno Guerci; Hiddo J.L. Heerspink; Baruch Itzhak; Linong Ji; Mikhail Kosiborod; Nebojša Lalić; Michael Lehrke; Nikolaus Marx; Michael Nauck; Helena W. Rodbard; Giuseppe M.C. Rosano; Peter Rossing; Lars Rydén; Francesca Santilli; Petra Maria Schumm-Draeger; Per Olav Vandvik; Tina Vilsbøll; Christoph Wanner; Carol Wysham; Eberhard Standl

doi:10.1186/s12933-022-01481-0

Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes

Oliver Schnell, Tadej Battelino, Richard Bergenstal, Matthias Blüher, Michael Böhm, Frank Brosius, Richard D. Carr, Antonio Ceriello, Thomas Forst, Francesco Giorgino, Bruno Guerci, Hiddo J.L. Heerspink, Baruch Itzhak, Linong Ji, Mikhail Kosiborod, Nebojša Lalić, Michael Lehrke, Nikolaus Marx, Michael Nauck, Helena W. RodbardGiuseppe M.C. Rosano, Peter Rossing, Lars Rydén, Francesca Santilli, Petra Maria Schumm-Draeger, Per Olav Vandvik, Tina Vilsbøll, Christoph Wanner, Carol Wysham, Eberhard Standl

Medicine

Research output: Contribution to journal › Comment/debate › peer-review

4 Scopus citations

Abstract

The 7th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Renal, and Glycemic Outcomes, was held virtually on November 18–19, 2021. Pursuing the tradition of the previous summits, this reference congress served as a platform for in-depth discussion and exchange on recently completed CVOTs. This year’s focus was placed on the outcomes of EMPEROR-Preserved, FIGARO-DKD, AMPLITUDE-O, SURPASS 1–5, and STEP 1–5. Trial implications for diabetes and obesity management and the impact on new treatment algorithms were highlighted for endocrinologists, diabetologists, cardiologists, nephrologists, and general practitioners. Discussions evolved from outcome trials using SGLT2 inhibitors as therapy for heart failure, to CVOTs with nonsteroidal mineralocorticoid receptor antagonists and GLP-1 receptor agonists. Furthermore, trials for glycemic and overweight/obesity management, challenges in diabetes management in COVID-19, and novel guidelines and treatment strategies were discussed. Trial registration The 8th Cardiovascular Outcome Trial Summit will be held virtually on November 10–11, 2022 (http://www.cvot.org).

Original language	English (US)
Article number	50
Journal	Cardiovascular Diabetology
Volume	21
Issue number	1
DOIs	https://doi.org/10.1186/s12933-022-01481-0
State	Published - Dec 2022

Keywords

Cardiovascular disease
Chronic kidney disease
Diabetes
GLP-1 receptor agonist
Heart failure
Living guidelines
Mineralocorticoid receptor antagonist
Obesity
SGLT2 inhibitor
Tirzepatide

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Cardiology and Cardiovascular Medicine

Access to Document

10.1186/s12933-022-01481-0

Cite this

Schnell, O., Battelino, T., Bergenstal, R., Blüher, M., Böhm, M., Brosius, F., Carr, R. D., Ceriello, A., Forst, T., Giorgino, F., Guerci, B., Heerspink, H. J. L., Itzhak, B., Ji, L., Kosiborod, M., Lalić, N., Lehrke, M., Marx, N., Nauck, M., ... Standl, E. (2022). Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes. Cardiovascular Diabetology, 21(1), [50]. https://doi.org/10.1186/s12933-022-01481-0

Schnell, O, Battelino, T, Bergenstal, R, Blüher, M, Böhm, M, Brosius, F, Carr, RD, Ceriello, A, Forst, T, Giorgino, F, Guerci, B, Heerspink, HJL, Itzhak, B, Ji, L, Kosiborod, M, Lalić, N, Lehrke, M, Marx, N, Nauck, M, Rodbard, HW, Rosano, GMC, Rossing, P, Rydén, L, Santilli, F, Schumm-Draeger, PM, Vandvik, PO, Vilsbøll, T, Wanner, C, Wysham, C & Standl, E 2022, 'Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes', Cardiovascular Diabetology, vol. 21, no. 1, 50. https://doi.org/10.1186/s12933-022-01481-0

@article{761ecda7a8c84255b3aea92464d6eafd,

title = "Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes",

abstract = "The 7th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Renal, and Glycemic Outcomes, was held virtually on November 18–19, 2021. Pursuing the tradition of the previous summits, this reference congress served as a platform for in-depth discussion and exchange on recently completed CVOTs. This year{\textquoteright}s focus was placed on the outcomes of EMPEROR-Preserved, FIGARO-DKD, AMPLITUDE-O, SURPASS 1–5, and STEP 1–5. Trial implications for diabetes and obesity management and the impact on new treatment algorithms were highlighted for endocrinologists, diabetologists, cardiologists, nephrologists, and general practitioners. Discussions evolved from outcome trials using SGLT2 inhibitors as therapy for heart failure, to CVOTs with nonsteroidal mineralocorticoid receptor antagonists and GLP-1 receptor agonists. Furthermore, trials for glycemic and overweight/obesity management, challenges in diabetes management in COVID-19, and novel guidelines and treatment strategies were discussed. Trial registration The 8th Cardiovascular Outcome Trial Summit will be held virtually on November 10–11, 2022 (http://www.cvot.org).",

keywords = "Cardiovascular disease, Chronic kidney disease, Diabetes, GLP-1 receptor agonist, Heart failure, Living guidelines, Mineralocorticoid receptor antagonist, Obesity, SGLT2 inhibitor, Tirzepatide",

author = "Oliver Schnell and Tadej Battelino and Richard Bergenstal and Matthias Bl{\"u}her and Michael B{\"o}hm and Frank Brosius and Carr, {Richard D.} and Antonio Ceriello and Thomas Forst and Francesco Giorgino and Bruno Guerci and Heerspink, {Hiddo J.L.} and Baruch Itzhak and Linong Ji and Mikhail Kosiborod and Neboj{\v s}a Lali{\'c} and Michael Lehrke and Nikolaus Marx and Michael Nauck and Rodbard, {Helena W.} and Rosano, {Giuseppe M.C.} and Peter Rossing and Lars Ryd{\'e}n and Francesca Santilli and Schumm-Draeger, {Petra Maria} and Vandvik, {Per Olav} and Tina Vilsb{\o}ll and Christoph Wanner and Carol Wysham and Eberhard Standl",

note = "Funding Information: The following authors declare competing interests: OS (Oliver Schnell): AstraZeneca, Bayer, Boehringer Ingelheim, Gr{\"u}nethal, Lilly, MSD, Mundipharma, Novo Nordisk, Roche, Sanofi, W{\"o}rwag. RB (Richard Bergenstal): Richard M. Bergenstal, MD has received research support, acted as a consultant, or been on the scientific advisory board for Abbott Diabetes Care, Ascensia, Bigfoot Biomedical, CeQur, DexCom, Eli Lilly, Hygieia, Insulet, Medtronic, Novo Nordisk, Onduo, Sanofi, United Healthcare and Zealand. Dr. Bergenstal{\textquoteright}s employer, non-profit HealthPartners Institute, contracts for his services and he receives no personal income for these services. MB (Matthias Bl{\"u}her): Honoraria as a consultant and speaker from Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Lilly, Novo Nordisk, Novartis, Pfizer, and Sanofi. MB (Michael B{\"o}hm): Research support (DFG, SFB-TTR 219, S-01): Deutsche Forschungsgemeinschaft; Speakers honoraria: Abbott, Amgen, Astra Zeneca, Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Cytokinetics, Edwards, Medtronic, Novartis, Servier, Vifor; Advisory board: Amgen, Bayer, Boehringer Ingelheim, Cytokinetics, Edwards, Medtronic, Novartis, Pfizer, ReCor, Servier, Vifor. HJLH (Hiddo Heerspink): Payments to my institution: AstraZeneca, Boehringer Ingelheim, Janssen, Novo Nordisk; Payments for consultancy to my institution: Dr. L Heerspink reports consulting fees from AstraZeneca, Abbvie, Boehringer Ingelheim, CSL Behring, Bayer, Chinook, Dimerix, Gilead, Goldfinch, Merck, NovoNordisk, Janssen, Travere Pharmaceuticals; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Institution: AstraZeneca. BI (Baruch Itzhak): Advisory Board, Consultancy, Lectures: Novo Nordisk, Sanofi, Eli Lilly, Bayer, AstraZeneca, Boehringer Ingelheim, Merck Sharp & Dohme, Pfizer, Roche Diagnostic, and Medtronic. MK (Mikhail Kosiborod): Research Grant: Astra Zeneca, Boehringer Ingelheim; Consultant/Advisory Board: Alnylam, Amgen, Applied Therapeutics, Astra Zeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Eli Lilly, Esperion Therapeutics, Janssen, Lexicon, Merck (Diabetes and Cardiovascular), Novo Nordisk, Pharmacosmos, Sanofi, Vifor Pharma; Other Research Support: Astra Zeneca; Honorarium: Astra Zeneca, Boehringer Ingelheim, Novo Nordisk. NM (Nikolaus Marx): Speaker: Abbott, AstraZeneca, Bayer, Boehringer Ingelheim / Lilly, Bristol-Myers Squibb, Novo Nordisk, Sanofi Aventis; Consultant: AstraZeneca, Bayer, Boehringer Ingelheim / Lilly, MSD, Novo Nordisk; Grant support: Boehringer Ingelheim, MSD. PR (Peter Rossing): Consultancy and/or speaking fees (to his institution) from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Gilead, MSD, Mundipharma, Novo Nordisk, Vifor, and Sanofi Aventis; Research grants from AstraZeneca and Novo Nordisk. LR (Lars Ryd{\'e}n): The authors declare that they have no competing interests. PMSD (Petra-Maria Schumm-Draeger): Grant to institution; Consulting fees: AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Sanofi, Lilly; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Boehringer Ingelheim, AstraZeneca, Lilly, Novo Nordisk, Sanofi, Hexal, AristoPharma, MSD, Berlin Chemie, Merck, GSK, BMS; Participation on a Data Safety Monitoring Board or Advisory Board: Sanofi, Novo Nordisk, Boehringer Ingelheim, Merck, BMS, AstraZeneca, GSK; Executive Board: European Federation of Internal Medicine; Leadership and executive board: German Society of Internal Medicine; Executive board: Professional German Society of Internal Medicine. POV (Per Olav Vandvik): CEO of MAGIC Evidence Ecosystem Foundation, responsible for MAGICapp as a platform to produce, publish and dynamically update guidelines. MAGIC supports WHO, NICE and other organisations in living guidelines. CW (Christoph Wanner): Grants to institution: Idorsia, Sanofi and Boehringer Ingelheim; Consulting fees: AstraZeneca, Boehringer Ingelheim, Idorsia, Bayer, GILEAD, GSK, and MSD; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Boehringer Ingelheim, AstraZeneca, FMC, Chiesi, Lilly, and Vifor; Participation on Data Safety Monitoring Board or Advisory Board: Sanofi and the Australasian Kidney Trials Network; Leadership: European Renal Association. TB (Tadej Battelino), FB (Frank Brosius), RDC (Richard D. Carr), AC (Antonio Ceriello), TF (Thomas Forst), FG (Francesco Giorgino), BC (Bruno Guerci), LJ (Linong Ji), NL (Neboj{\v s}a Lali{\'c}), ML (Michael Lehrke), MN (Michael Nauck), HWR (Helena W. Rodbard), GMCR (Giuseppe M.C. Rosano), FS (Francesca Santilli), TV (Tina Vilsb{\o}ll), CW (Carol Wysham), ES (Eberhard Standl) did not declare any competing interests. Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = dec,

doi = "10.1186/s12933-022-01481-0",

language = "English (US)",

volume = "21",

journal = "Cardiovascular Diabetology",

issn = "1475-2840",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Report from the CVOT Summit 2021

T2 - new cardiovascular, renal, and glycemic outcomes

AU - Schnell, Oliver

AU - Battelino, Tadej

AU - Bergenstal, Richard

AU - Blüher, Matthias

AU - Böhm, Michael

AU - Brosius, Frank

AU - Carr, Richard D.

AU - Ceriello, Antonio

AU - Forst, Thomas

AU - Giorgino, Francesco

AU - Guerci, Bruno

AU - Heerspink, Hiddo J.L.

AU - Itzhak, Baruch

AU - Ji, Linong

AU - Kosiborod, Mikhail

AU - Lalić, Nebojša

AU - Lehrke, Michael

AU - Marx, Nikolaus

AU - Nauck, Michael

AU - Rodbard, Helena W.

AU - Rosano, Giuseppe M.C.

AU - Rossing, Peter

AU - Rydén, Lars

AU - Santilli, Francesca

AU - Schumm-Draeger, Petra Maria

AU - Vandvik, Per Olav

AU - Vilsbøll, Tina

AU - Wanner, Christoph

AU - Wysham, Carol

AU - Standl, Eberhard

N1 - Funding Information: The following authors declare competing interests: OS (Oliver Schnell): AstraZeneca, Bayer, Boehringer Ingelheim, Grünethal, Lilly, MSD, Mundipharma, Novo Nordisk, Roche, Sanofi, Wörwag. RB (Richard Bergenstal): Richard M. Bergenstal, MD has received research support, acted as a consultant, or been on the scientific advisory board for Abbott Diabetes Care, Ascensia, Bigfoot Biomedical, CeQur, DexCom, Eli Lilly, Hygieia, Insulet, Medtronic, Novo Nordisk, Onduo, Sanofi, United Healthcare and Zealand. Dr. Bergenstal’s employer, non-profit HealthPartners Institute, contracts for his services and he receives no personal income for these services. MB (Matthias Blüher): Honoraria as a consultant and speaker from Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Lilly, Novo Nordisk, Novartis, Pfizer, and Sanofi. MB (Michael Böhm): Research support (DFG, SFB-TTR 219, S-01): Deutsche Forschungsgemeinschaft; Speakers honoraria: Abbott, Amgen, Astra Zeneca, Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Cytokinetics, Edwards, Medtronic, Novartis, Servier, Vifor; Advisory board: Amgen, Bayer, Boehringer Ingelheim, Cytokinetics, Edwards, Medtronic, Novartis, Pfizer, ReCor, Servier, Vifor. HJLH (Hiddo Heerspink): Payments to my institution: AstraZeneca, Boehringer Ingelheim, Janssen, Novo Nordisk; Payments for consultancy to my institution: Dr. L Heerspink reports consulting fees from AstraZeneca, Abbvie, Boehringer Ingelheim, CSL Behring, Bayer, Chinook, Dimerix, Gilead, Goldfinch, Merck, NovoNordisk, Janssen, Travere Pharmaceuticals; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Institution: AstraZeneca. BI (Baruch Itzhak): Advisory Board, Consultancy, Lectures: Novo Nordisk, Sanofi, Eli Lilly, Bayer, AstraZeneca, Boehringer Ingelheim, Merck Sharp & Dohme, Pfizer, Roche Diagnostic, and Medtronic. MK (Mikhail Kosiborod): Research Grant: Astra Zeneca, Boehringer Ingelheim; Consultant/Advisory Board: Alnylam, Amgen, Applied Therapeutics, Astra Zeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Eli Lilly, Esperion Therapeutics, Janssen, Lexicon, Merck (Diabetes and Cardiovascular), Novo Nordisk, Pharmacosmos, Sanofi, Vifor Pharma; Other Research Support: Astra Zeneca; Honorarium: Astra Zeneca, Boehringer Ingelheim, Novo Nordisk. NM (Nikolaus Marx): Speaker: Abbott, AstraZeneca, Bayer, Boehringer Ingelheim / Lilly, Bristol-Myers Squibb, Novo Nordisk, Sanofi Aventis; Consultant: AstraZeneca, Bayer, Boehringer Ingelheim / Lilly, MSD, Novo Nordisk; Grant support: Boehringer Ingelheim, MSD. PR (Peter Rossing): Consultancy and/or speaking fees (to his institution) from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Gilead, MSD, Mundipharma, Novo Nordisk, Vifor, and Sanofi Aventis; Research grants from AstraZeneca and Novo Nordisk. LR (Lars Rydén): The authors declare that they have no competing interests. PMSD (Petra-Maria Schumm-Draeger): Grant to institution; Consulting fees: AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Sanofi, Lilly; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Boehringer Ingelheim, AstraZeneca, Lilly, Novo Nordisk, Sanofi, Hexal, AristoPharma, MSD, Berlin Chemie, Merck, GSK, BMS; Participation on a Data Safety Monitoring Board or Advisory Board: Sanofi, Novo Nordisk, Boehringer Ingelheim, Merck, BMS, AstraZeneca, GSK; Executive Board: European Federation of Internal Medicine; Leadership and executive board: German Society of Internal Medicine; Executive board: Professional German Society of Internal Medicine. POV (Per Olav Vandvik): CEO of MAGIC Evidence Ecosystem Foundation, responsible for MAGICapp as a platform to produce, publish and dynamically update guidelines. MAGIC supports WHO, NICE and other organisations in living guidelines. CW (Christoph Wanner): Grants to institution: Idorsia, Sanofi and Boehringer Ingelheim; Consulting fees: AstraZeneca, Boehringer Ingelheim, Idorsia, Bayer, GILEAD, GSK, and MSD; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Boehringer Ingelheim, AstraZeneca, FMC, Chiesi, Lilly, and Vifor; Participation on Data Safety Monitoring Board or Advisory Board: Sanofi and the Australasian Kidney Trials Network; Leadership: European Renal Association. TB (Tadej Battelino), FB (Frank Brosius), RDC (Richard D. Carr), AC (Antonio Ceriello), TF (Thomas Forst), FG (Francesco Giorgino), BC (Bruno Guerci), LJ (Linong Ji), NL (Nebojša Lalić), ML (Michael Lehrke), MN (Michael Nauck), HWR (Helena W. Rodbard), GMCR (Giuseppe M.C. Rosano), FS (Francesca Santilli), TV (Tina Vilsbøll), CW (Carol Wysham), ES (Eberhard Standl) did not declare any competing interests. Publisher Copyright: © 2022, The Author(s).

PY - 2022/12

Y1 - 2022/12

N2 - The 7th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Renal, and Glycemic Outcomes, was held virtually on November 18–19, 2021. Pursuing the tradition of the previous summits, this reference congress served as a platform for in-depth discussion and exchange on recently completed CVOTs. This year’s focus was placed on the outcomes of EMPEROR-Preserved, FIGARO-DKD, AMPLITUDE-O, SURPASS 1–5, and STEP 1–5. Trial implications for diabetes and obesity management and the impact on new treatment algorithms were highlighted for endocrinologists, diabetologists, cardiologists, nephrologists, and general practitioners. Discussions evolved from outcome trials using SGLT2 inhibitors as therapy for heart failure, to CVOTs with nonsteroidal mineralocorticoid receptor antagonists and GLP-1 receptor agonists. Furthermore, trials for glycemic and overweight/obesity management, challenges in diabetes management in COVID-19, and novel guidelines and treatment strategies were discussed. Trial registration The 8th Cardiovascular Outcome Trial Summit will be held virtually on November 10–11, 2022 (http://www.cvot.org).

AB - The 7th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Renal, and Glycemic Outcomes, was held virtually on November 18–19, 2021. Pursuing the tradition of the previous summits, this reference congress served as a platform for in-depth discussion and exchange on recently completed CVOTs. This year’s focus was placed on the outcomes of EMPEROR-Preserved, FIGARO-DKD, AMPLITUDE-O, SURPASS 1–5, and STEP 1–5. Trial implications for diabetes and obesity management and the impact on new treatment algorithms were highlighted for endocrinologists, diabetologists, cardiologists, nephrologists, and general practitioners. Discussions evolved from outcome trials using SGLT2 inhibitors as therapy for heart failure, to CVOTs with nonsteroidal mineralocorticoid receptor antagonists and GLP-1 receptor agonists. Furthermore, trials for glycemic and overweight/obesity management, challenges in diabetes management in COVID-19, and novel guidelines and treatment strategies were discussed. Trial registration The 8th Cardiovascular Outcome Trial Summit will be held virtually on November 10–11, 2022 (http://www.cvot.org).

KW - Cardiovascular disease

KW - Chronic kidney disease

KW - Diabetes

KW - GLP-1 receptor agonist

KW - Heart failure

KW - Living guidelines

KW - Mineralocorticoid receptor antagonist

KW - Obesity

KW - SGLT2 inhibitor

KW - Tirzepatide

UR - http://www.scopus.com/inward/record.url?scp=85127836619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85127836619&partnerID=8YFLogxK

U2 - 10.1186/s12933-022-01481-0

DO - 10.1186/s12933-022-01481-0

M3 - Comment/debate

C2 - 35395808

AN - SCOPUS:85127836619

SN - 1475-2840

VL - 21

JO - Cardiovascular Diabetology

JF - Cardiovascular Diabetology

IS - 1

M1 - 50

ER -

Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this